MammoReader clears FDA

Article

Intelligent Systems Software in Boca Raton, FL, announced Jan. 17 that the FDA had cleared its computer-aided detection (CAD) system, MammoReader. The product is designed to help

Intelligent Systems Software in Boca Raton, FL, announced Jan. 17 that the FDA had cleared its computer-aided detection (CAD) system, MammoReader. The product is designed to help in early detection of breast cancer by increasing the detection of subtle signs of cancer. The system is cleared for both screening and diagnostic use. Supporting the company's FDA application were clinical data from 327 cancer cases, which showed that breast cancer in 23% of the women diagnosed with the disease could have been discovered an average of 14 months earlier on screening mammograms, if MammoReader had been used, according to the company. MammoReader analyses are based on digitized mammograms. The systems, which will be marketed by Instrumentarium, will be priced at $99,500 and up.

Recent Videos
SNMMI: Emerging PET Insights on Neuroinflammation with Progressive Apraxia of Speech (PAOS) and Parkinson-Plus Syndrome
Improving Access to Nuclear Imaging: An Interview with SNMMI President Jean-Luc C. Urbain, MD, PhD
SNMMI: 18F-Piflufolastat PSMA PET/CT Offers High PPV for Local PCa Recurrence Regardless of PSA Level
SNMMI: NIH Researcher Discusses Potential of 18F-Fluciclovine for Multiple Myeloma Detection
SNMMI: What Tau PET Findings May Reveal About Modifiable Factors for Alzheimer’s Disease
Emerging Insights on the Use of FES PET for Women with Lobular Breast Cancer
Can Generative AI Reinvent Radiology Reporting?: An Interview with Samir Abboud, MD
Mammography Study Reveals Over Sixfold Higher Risk of Advanced Cancer Presentation with Symptom-Detected Cancers
Combining Advances in Computed Tomography Angiography with AI to Enhance Preventive Care
Study: MRI-Based AI Enhances Detection of Seminal Vesicle Invasion in Prostate Cancer
Related Content
© 2025 MJH Life Sciences

All rights reserved.